STF-1084
Based on 1 Customer Validation
STF-1084 is a specific, cell-impermeable, competitive inhibitor of ENPP1 (Ki = 33 nM). STF-1084 increases extracellular cGAMP concentrations by preventing its degradation by ENPP1, thereby enhancing immune infiltration. STF-1084 acts synergistically with ionizing radiation (IR) and cGAMP to delay tumor progression. STF-1084 can be used to study cancers with low immunogenicity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.92%
- No. CAS: 2298390-71-1
- Fòrmula: C17H24N3O5P
- Peso molecular:381.36
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
STF-1084 (0.1-106 nM) inhibits extracellular cGAMP degradation (IC50 = 340 nM), but does not affect intracellular cGAMP in human ENPP1 transfected into 293T cGAS ENPP1−/− cells[1].
STF-1084 (10 μM) induces IFNB1 expression in CD14+ human ENPP1 transfected into 293T cGAS ENPP1−/− cells[1].
STF-1084 (50 μM, 48 h) increases extracellular cGAMP in 4T1-luc cells, E0771 cells, MC38 cells, MDA-MB-231 cells, MCF-7 cells and NMuMG cells via IR stimulation [1].
STF-1084 (1-106 nM) has low activity towards the ectonucleotidases alkaline phosphatase (Ki,app > 100 μM) and ENPP2 (Ki,app = 5.5 μM)[1].
STF-1084 (0.1-106 nM, 16 h) is non-toxic to primary human PBMCs[1].
STF-1084 (50 μM, 16 h) has no effect on cytokine production when cGAMP was electroporated into primary human PBMCs[1].
STF-1084 shows high stability (t1/2; 159 min) in both human and mouse liver microsomes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:WT BALB/cJ mice (Five- to nine-week-old female mice) bearing 4T1-luc cells ((1x106) were orthotopically injected on day 0)[1]
-
Dosage:100 μL of 1 mM
-
Administration:intratumoral injections, once, on day 0, 2, 4, and 7 after IR
-
Result:Increased expression of tumor-associated CD11c+ population, delayed tumor progression synergized with IR and cGAMP.
Chemical Information
-
No. CAS 2298390-71-1
-
Appearance Solid
-
Peso molecular 381.36
-
Fòrmula C17H24N3O5P
-
Color White to off-white
-
SMILES
OP(O)(CCC1CCN(C2=C3C=C(OC)C(OC)=CC3=NC=N2)CC1)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
DMSO : 12 mg/mL (31.47 mM; ultrasonic and adjust pH to 1 with 1 M HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.2 mg/mL (3.15 mM); Clear solution
This protocol yields a clear solution of ≥ 1.2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.2 mg/mL (3.15 mM); Clear solution
This protocol yields a clear solution of ≥ 1.2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (277 KB)
-
SDS (615 KB)
- English - EN (615 KB)
- Français - FR (615 KB)
- Deutsch - DE (615 KB)
- Norwegian - NO (615 KB)
- Español - ES (615 KB)
- Swedish - SV (615 KB)
- Italian - IT (615 KB)
- Korean - KR (615 KB)
- Portuguese - PT (615 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6222 mL | 13.1110 mL | 26.2219 mL | 65.5549 mL |
| 5 mM | 0.5244 mL | 2.6222 mL | 5.2444 mL | 13.1110 mL | |
| 10 mM | 0.2622 mL | 1.3111 mL | 2.6222 mL | 6.5555 mL | |
| 15 mM | 0.1748 mL | 0.8741 mL | 1.7481 mL | 4.3703 mL | |
| 20 mM | 0.1311 mL | 0.6555 mL | 1.3111 mL | 3.2777 mL | |
| 25 mM | 0.1049 mL | 0.5244 mL | 1.0489 mL | 2.6222 mL | |
| 30 mM | 0.0874 mL | 0.4370 mL | 0.8741 mL | 2.1852 mL |
STF-1084 Related Classifications
HY-141831 Related Classifications
Powered by Bioz